Skip to content

This study is to find out which antibiotic injection is better for treating infection of the abdominal fluid in patients with liver disease.

Efficacy of cefaperazone -sulbactam versus ceftriaxone in the early resolution of Spontaneous Bacterial Peritonitis– A Randomised Controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047518
Enrollment
68
Registered
2022-11-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K652- Spontaneous bacterial peritonitis

Interventions

Intervention1: CEFOPERAZONE SULBACTAM: INTERVENTION ARM will receive 1.5 gram of intravenous Cefoperazone sulbactam twice a day for 7 days Control Intervention1: CEFTRIAXONE: COMPARATOR ARM will recei

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cirrhosis patients, in whom there is a clinical suspicion of SBP or ascitic fluid has more than 250 polymorphonuclear cells on microscopy will be included in this study.

Exclusion criteria

Exclusion criteria: Following patients will be excluded Secondary bacterial peritonitis Peritonial tuberculosis Patient with hepto cellular carcinoma Previous cultures positive for resistant bacteria to third generation cephalosporins Allergy to third generation cephalosporin

Design outcomes

Primary

MeasureTime frame
1.To compare early resolution rates of SBP after 48 hours of antibiotic administration between the two groups 2. To compare the resolution rates of SBP after 7 days of antibiotic administration between the two groupsTimepoint: 48 hours and 7 days

Secondary

MeasureTime frame
1. To compare the proportion of patients who develop new organ failure at 48 hours in the two groups using SOFA Score 2. To compare the mortality rates between the two groups at 30 and 90 days 3. To compare the length of hospital stay between the two groupsTimepoint: 48 hours, 30 days, 90 days

Countries

India

Contacts

Public ContactSRIDHARA K

JIPMER

mukta.wyawahare@gmail.com08903307660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026